

## **Bexil Corporation Announces First Quarter 2018 Financial Results**

May 4, 2018 – Bexil Corporation (BXLC) today reported its financial results for the first quarter ended March 31, 2018.

For the three months ended March 31, 2018, Bexil recorded a net loss attributable to Bexil shareholders of approximately \$0.90 million or \$1.00 of loss per share, compared to net income attributable to Bexil shareholders of approximately \$0.34 million or \$0.35 of diluted earnings per share for the three months ended March 31, 2017.

The Company's book value per share attributable to Bexil shareholders at March 31, 2018 was \$20.85, based on shareholders' equity attributable to Bexil shareholders of approximately \$18.6 million and 892,843 shares issued and outstanding.

The Company's unaudited balance sheet, statements of comprehensive income, and statements of cash flows as of and for the three months ended March 31, 2018 are appended to the copy of this press release on [www.Bexil.com](http://www.Bexil.com).

### **About Bexil Corporation**

Bexil is engaged through a subsidiary in investment management. To learn more about Bexil, including Rule 15c2-11 information, please visit [www.Bexil.com](http://www.Bexil.com).

### **Safe Harbor Note**

This release contains certain “forward looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Bexil, which may cause the Company's actual results to be materially different from those expressed or implied by such statements. Investors should carefully consider the risks, uncertainties and other factors, together with all of the other information included in the Company's Annual Report, at <http://www.bexil.com/cautionary-language.html>, and similar information. The forward looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward looking statements to reflect subsequent events or circumstances.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor's understanding of the Company's underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders' equity attributable to Bexil shareholders divided by currently issued and outstanding shares.

Contact: Thomas O'Malley  
Chief Financial Officer  
1-212-785-0900, ext. 267  
[tomalley@bexil.com](mailto:tomalley@bexil.com)  
[www.Bexil.com](http://www.Bexil.com)

**BEXIL CORPORATION**  
**CONSOLIDATED BALANCE SHEET**  
**March 31, 2018**  
**(Unaudited)**

**Assets**

Cash and cash equivalents	\$ 1,299,135
Investments in securities	16,532,549
Accounts receivable	223,211
Intangible asset, net	2,072,396
Total assets	<u>\$ 20,127,291</u>

**Liabilities and equity**

Accounts payable and accrued expenses	\$ 1,352,780
Margin loan	296,107
Payable for securities purchased	29,754
Total liabilities	<u>1,678,641</u>

Commitments and Contingencies

**Equity**

Bexil Corporation shareholders' equity	
Common stock, \$0.01 par value, 9,900,000 shares authorized; 892,843 issued and outstanding	8,929
Series A participating preferred stock, \$0.01 par value, 100,000 shares authorized; zero shares issued and outstanding	—
Additional paid in capital	15,302,732
Notes receivable for common stock issued	(1,242,349)
Accumulated other comprehensive loss	(3,173)
Retained earnings	4,548,296
Total Bexil Corporation shareholders' equity	<u>18,614,435</u>
Noncontrolling interests in subsidiary	<u>(165,785)</u>
Total equity	<u>18,448,650</u>
Total liabilities and equity	<u>\$ 20,127,291</u>

**BEXIL CORPORATION**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**  
**Three Months Ended March 31, 2018 and 2017**  
**(Unaudited)**

	<b>2018</b>	<b>2017</b>
<b>Revenues</b>		
Management and other fees	\$ 551,689	\$ 456,305
Dividends and interest	184,119	145,029
Realized gain (loss) on investments in securities	(1,673)	45,353
Unrealized gain (loss) on investments in securities	(1,155,307)	178,639
	(421,172)	825,326
<b>Expenses</b>		
Compensation and benefits	311,103	294,988
General and administrative	135,864	139,923
Professional services	31,913	50,406
	478,880	485,317
Income (loss) before taxes	(900,052)	340,009
Income tax expense	—	27
Net income (loss)	(900,052)	339,982
Net loss attributable to noncontrolling interests	183	122
Net income (loss) attributable to Bexil Corporation shareholders	\$ (899,869)	\$ 340,104
Net income (loss) per share		
Basic, attributable to Bexil Corporation shareholders	\$ (1.00)	\$ 0.35
Diluted attributable to Bexil Corporation shareholders	\$ (1.00)	\$ 0.35
Weighted average shares outstanding		
Basic	896,095	969,914
Diluted	896,095	984,940
Other comprehensive loss, net of tax		
Unrealized loss on investment securities	(382)	(318)
Other comprehensive loss	(382)	(318)
Comprehensive income (loss)	(900,434)	339,664
Comprehensive loss attributable to noncontrolling interests	183	122
Comprehensive income (loss) attributable to Bexil Corporation shareholders	\$ (900,251)	\$ 339,786

**BEXIL CORPORATION**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**Three Months Ended March 31, 2018 and 2017**  
**(Unaudited)**

	<u>2018</u>	<u>2017</u>
<b>Cash flows from operating activities</b>		
Net income (loss)	\$ (900,052)	\$ 339,982
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities		
Purchase of investment securities	(3,836,559)	(2,227,054)
Proceeds on sales of investment securities	1,415,645	2,448,833
Stock-based compensation expense	11,106	16,085
Realized loss (gain) on investments in securities	1,673	(45,353)
Unrealized loss (gain) on investments in securities	1,155,307	(177,661)
Amortization	90,104	90,104
Increase in accounts receivable	(27,775)	(134,368)
Decrease in accounts payable and accrued expenses	(21,367)	(59,083)
Increase in payable for securities purchases	29,754	91,802
Increase in margin loan	296,107	—
Increase in securities sold, not yet purchased	—	32,136
Net cash (used in) provided by operating activities	<u>(1,786,057)</u>	<u>375,423</u>
<b>Cash flows from investing activities</b>		
Proceeds on sale investment securities	—	244,486
Net cash provided by investing activities	<u>—</u>	<u>244,486</u>
<b>Cash flows from financing activities</b>		
Common stock issued upon exercise of stock options	107	—
Proceeds from promissory notes accepted for common stock issued	16,267	18,800
Common stock repurchases	(144,733)	(703,711)
Net cash used in financing activities	<u>(128,359)</u>	<u>(684,911)</u>
Net decrease in cash and cash equivalents	(1,914,416)	(65,002)
Cash and cash equivalents, beginning of period	3,213,551	1,671,550
Cash and cash equivalents, end of period	<u>\$ 1,299,135</u>	<u>\$ 1,606,548</u>
<b>Supplemental disclosures</b>		
Interest paid	\$ 1,496	\$ 324
Income taxes paid	\$ —	\$ 27